Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

47.87 +3.29 (+7.38%)

Streaming Delayed Price Updated: 11:01 AM EST, Nov 18, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	3,704,716
Open	48.30
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	44.58
Today's Range	47.78 - 48.64
52wk Range	34.10 - 46.00
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results ↗

Today 10:20 EST

Roche was evaluating Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer.

Via Stocktwits

Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why ↗

Today 9:56 EST

Roche posts positive phase 3 results for giredestrant in early breast cancer, showing improved disease-free survival and a favorable safety profile.

Via Benzinga

Performance

YTD	+37.0%	+37.0%
1 Month	+8.6%	+8.6%
3 Month	+20.9%	+20.9%
6 Month	+21.9%	+21.9%
1 Year	+34.2%	+34.2%

More News

Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 200% ↗

Today 9:19 EST

Via Investor's Business Daily

2 No-Brainer Healthcare Stocks to Buy Now ↗

Today 6:45 EST

Via The Motley Fool

Genentech’s Giredestrant Becomes the First Oral SERD to Show Superior Invasive Disease-Free Survival in Early Breast Cancer

Today 1:10 EST

From Genentech

Via Business Wire

Magnificent Seven Will Become Low-Profit Tech Utilities, Analyst Warns ↗

November 17, 2025

Via Benzinga

Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer ↗

November 17, 2025

Via Investor's Business Daily

Why Roche Holding Stock Popped Today ↗

November 10, 2025

Via The Motley Fool

TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results ↗

November 10, 2025

Via Investor's Business Daily

Multimodal AI Unleashes New Era in Cancer Research: A Revolution in Diagnosis and Treatment

November 10, 2025

Via TokenRing AI

Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis

November 10, 2025

From Genentech

Via Business Wire

Celcuity Eyeing Cancer Treatment Riddle. Stock Flys 534% This Year. ↗

November 05, 2025

Via Investor's Business Daily

AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential

November 04, 2025

Via TokenRing AI

Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025

November 03, 2025

From Genentech

Via Business Wire

Positive Phase III Data for Genentech’s Gazyva Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus

November 03, 2025

From Genentech

Via Business Wire

AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future

October 31, 2025

Via TokenRing AI

Positive Phase III Results for Genentech’s Gazyva in Children and Young Adults With Idiopathic Nephrotic Syndrome

October 28, 2025

From Genentech

Via Business Wire

Top 3 Health Care Stocks You'll Regret Missing In October ↗

October 21, 2025

Via Benzinga

Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results ↗

October 20, 2025

Via Benzinga

S&P 500's Resurgence: A Deep Dive into Market Dynamics and Future Trajectories

October 23, 2025

Via MarketMinute

Top 1% Celcuity Shoots To Record High On Roche-Rivaling Breast Cancer Results ↗

October 20, 2025

Via Investor's Business Daily

Rapt Therapeutics, Outperforming 98% Of All Stocks, Skyrockets After Topping Roche ↗

October 20, 2025

Via Investor's Business Daily

Genentech’s Tecentriq Showed Significant Overall and Disease-Free Survival Benefits in Bladder Cancer With ctDNA-Guided Treatment

October 20, 2025

From Genentech

Via Business Wire

FDA Approves Genentech’s Gazyva for the Treatment of Lupus Nephritis

October 20, 2025

From Genentech

Via Business Wire

Genentech’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer

October 18, 2025

From Genentech

Via Business Wire

Frequently Asked Questions

Is Roche Holding AG Basel American Depositary Shares publicly traded?

Yes, Roche Holding AG Basel American Depositary Shares is publicly traded.

What exchange does Roche Holding AG Basel American Depositary Shares trade on?

Roche Holding AG Basel American Depositary Shares trades on the OTC Traded

What is the ticker symbol for Roche Holding AG Basel American Depositary Shares?

The ticker symbol for Roche Holding AG Basel American Depositary Shares is RHHBY on the OTC Traded

What is the current price of Roche Holding AG Basel American Depositary Shares?

The current price of Roche Holding AG Basel American Depositary Shares is 47.87

When was Roche Holding AG Basel American Depositary Shares last traded?

The last trade of Roche Holding AG Basel American Depositary Shares was at 11/18/25 11:01 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.